Coherus Oncology (CHRS) Long-Term Investments (2018 - 2026)

Coherus Oncology has disclosed Long-Term Investments across 8 years of filings, most recently posting $8.4 million for Q2 2026.

• In Q2 2026, Long-Term Investments changed N/A year-over-year to $8.4 million; the TTM figure through Jun 2026 stood at $8.4 million (changed N/A YoY), while the FY2023 annual figure was $67.5 million, down 11.49% from the prior year.
• Long-Term Investments came in at $8.4 million for Q2 2026 at Coherus Oncology, down from $9.7 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $79.0 million in Q3 2023 to a low of $8.4 million in Q2 2026.
• Average Long-Term Investments over 4 years is $59.2 million, with a median of $65.6 million recorded in 2024.
• Year-over-year, Long-Term Investments soared 67.05% in 2022 and dropped 21.88% in 2024.
• Over 4 years, Long-Term Investments stood at $76.3 million in 2022, then decreased by 11.49% to $67.5 million in 2023, then grew by 5.75% to $71.4 million in 2024, then sank by 88.2% to $8.4 million in 2026.
• Per Business Quant data, the three most recent Long-Term Investments figures were $8.4 million in Q2 2026, $9.7 million in Q1 2026, and $71.4 million in Q3 2024.